Merck preaches the value of ‘focus’ as it spins off $6.5B women’s health, biosimilars units
admin 5th February 2020 Uncategorised 0Merck’s plan to shed its women’s health, biosimilars and legacy products in a spinoff will let the company focus on oncology and other fast-growing sectors, CEO Ken Frazier said. But Wall Street analysts worry the company still relies too much on immuno-oncology blockbuster Keytruda—and they’re not sure the spinoff will remedy that.
More: Merck preaches the value of ‘focus’ as it spins off .5B women’s health, biosimilars units
Source: fierce